Skip to the beginning of the images gallery

Voglibose - 98%, high purity , Alpha glucosidase inhibitor, CAS No.83480-29-9, Alpha glucosidase inhibitor

≥98%

CAS#: 83480-29-9
Formula: C₁₀H₂₁NO₇
Molecular Weight: 267.28
MDL number: MFCD00865496
PubChem CID: 444020

Item Number

V121714

Grouped product items
SKU	Size	Availability	Price
V121714-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$13.90
V121714-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$52.90
V121714-50mg	50mg	In stock	$82.90
V121714-100mg	100mg	In stock	$122.90
V121714-500mg	500mg	In stock	$553.90

α-glucosidase inhibitor

View related series

Pharmaceutical ingredients

Basic Description

Synonyms	voglibose \| 83480-29-9 \| Basen \| Glustat \| AO-128 \| AO 128 \| A-71100 \| (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol \| CHEMBL476960 \| DTXSID2021442 \| S77P977AG8 \| 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(h
Specifications & Purity	≥98%
Biochemical and Physiological Mechanisms	Orally activeα-glucosidase inhibitor (IC50values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases Glukagon-like peptide 1 (GLP-1) secretion and decreases food consumption inob/obmice, and reduces plasma concentrations of glucose, triglyc
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Action Type	INHIBITOR
Mechanism of action	Alpha glucosidase inhibitor
Product Description	Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through Glukagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway. Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through Glukagon-like peptide receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.

Associated Targets(Human)

GAA Tclin Lysosomal alpha-glucosidase (1 Activities)

Discover Target: GAA

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MGAM Tclin Maltase-glucoamylase (654 Activities)

Discover Target: MGAM

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ESR1 Tclin Estrogen receptor alpha (17718 Activities)

Discover Target: ESR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NR3C1 Tclin Glucocorticoid receptor (14987 Activities)

Discover Target: NR3C1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PGR Tclin Progesterone receptor (8562 Activities)

Discover Target: PGR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)

Discover Target: ADRB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)

Discover Target: CHRM2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)

Discover Target: ADRB1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)

Discover Target: HTR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)

Discover Target: ADRA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AR Tclin Androgen Receptor (11781 Activities)

Discover Target: AR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)

Discover Target: CHRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD2 Tclin Dopamine D2 receptor (23596 Activities)

Discover Target: DRD2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)

Discover Target: GABRA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAOA Tclin Monoamine oxidase A (11911 Activities)

Discover Target: MAOA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)

Discover Target: CNR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD1 Tclin Dopamine D1 receptor (9720 Activities)

Discover Target: DRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)

Discover Target: PTGS1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A2 Tclin Norepinephrine transporter (10102 Activities)

Discover Target: SLC6A2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH2 Tclin Histamine H2 receptor (5428 Activities)

Discover Target: HRH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)

Discover Target: HTR2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)

Discover Target: HTR2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)

Discover Target: AVPR2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA1 Tclin Adenosine A1 receptor (17603 Activities)

Discover Target: ADORA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)

Discover Target: AGTR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A4 Tclin Serotonin transporter (12625 Activities)

Discover Target: SLC6A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)

Discover Target: ADRA1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)

Discover Target: PTGS2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH1 Tclin Histamine H1 receptor (7573 Activities)

Discover Target: HRH1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRM1 Tclin Mu opioid receptor (19785 Activities)

Discover Target: OPRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD3 Tclin Dopamine D3 receptor (14368 Activities)

Discover Target: DRD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)

Discover Target: AVPR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRD1 Tclin Delta opioid receptor (15096 Activities)

Discover Target: OPRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRK1 Tclin Kappa opioid receptor (16155 Activities)

Discover Target: OPRK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)

Discover Target: HTR3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A3 Tclin Dopamine transporter (10535 Activities)

Discover Target: SLC6A3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)

Discover Target: GRIN1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KCNH2 Tclin HERG (29587 Activities)

Discover Target: KCNH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)

Discover Target: CACNA1C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE3A Tclin Phosphodiesterase 3A (3309 Activities)

Discover Target: PDE3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)

Discover Target: SLC29A1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)

Discover Target: ADRA2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)

Discover Target: ADRA2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)

Discover Target: CHRM3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)

Discover Target: HTR2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TBXA2R Tclin Thromboxane A2 receptor (5717 Activities)

Discover Target: TBXA2R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA2A Tclin Adenosine A2a receptor (16305 Activities)

Discover Target: ADORA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA3 Tchem Adenosine A3 receptor (15931 Activities)

Discover Target: ADORA3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BDKRB2 Tclin Bradykinin B2 receptor (3970 Activities)

Discover Target: BDKRB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH3 Tclin Histamine H3 receptor (10389 Activities)

Discover Target: HRH3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRNA4 Tclin Neuronal acetylcholine receptor protein alpha-4 subunit (1265 Activities)

Discover Target: CHRNA4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Mc4r Melanocortin receptor 4 (1205 Activities)

Discover Target: Mc4r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Npy1r Neuropeptide Y receptor type 1 (8 Activities)

Discover Target: Npy1r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Cckar Cholecystokinin A receptor (90 Activities)

Discover Target: Cckar

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Pde4d Phosphodiesterase 4D (4 Activities)

Discover Target: Pde4d

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Hdac6 Histone deacetylase 6 (222 Activities)

Discover Target: Hdac6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Lct Lactase-glycosylceramidase (87 Activities)

Discover Target: Lct

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Gaa Acidic alpha-glucosidase (551 Activities)

Discover Target: Gaa

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rattus norvegicus (775804 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SARS-CoV-2 (38078 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Names and Identifiers

IUPAC Name	(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
INCHI	InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChi Key	FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Canonical SMILES	C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
Isomeric SMILES	C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
WGK Germany	3
RTECS	NM7524600
PubChem CID	444020
Molecular Weight	267.28
Reaxy-Rn	5430708

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

4 results found

Lot Number	Certificate Type	Date	Item
A2411839	Certificate of Analysis	Nov 22, 2023	V121714
A2411840	Certificate of Analysis	Nov 22, 2023	V121714
A2411841	Certificate of Analysis	Nov 22, 2023	V121714
H2106248	Certificate of Analysis	Jun 21, 2021	V121714

Chemical and Physical Properties

Solubility	Solvent:water, Max Conc. mg/mL: 26.73, Max Conc. mM: 100; Solvent:DMSO, Max Conc. mg/mL: 20.05, Max Conc. mM: 75
Sensitivity	Heat sensitive
Specific Rotation[α]	46°(C=1,0.1mol/L HCL)
Melt Point(°C)	165°C

Safety and Hazards(GHS)

WGK Germany	3
RTECS	NM7524600
Reaxy-Rn	5430708
Merck Index	10029

References

1. T Hara,N Hotta. (1998-01-22) [Voglibose].. Nihon rinsho. Japanese journal of clinical medicine, 55 Suppl (114-119). [PMID:9434453]
2. Jiro Nakamura. (2005-03-23) [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].. Nihon rinsho. Japanese journal of clinical medicine, 63 Suppl 2 (457-461). [PMID:15779422]
3. Ryuzo Kawamori. (2010-05-08) [Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].. Nihon rinsho. Japanese journal of clinical medicine, 68 ((5)): (873-881). [PMID:20446586]
4. Y Iwamoto,A Kashiwagi,N Yamada,S Terao,N Mimori,M Suzuki,H Tachibana. (2010-07-02) Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.. Diabetes, obesity & metabolism, 12 ((8)): (700-708). [PMID:20590747]
5. Yasuhiro Shimojima,Wataru Ishii,Masayuki Matsuda,Kana Tojo,Rie Watanabe,Shu-Ichi Ikeda. (2011-01-18) Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.. Modern rheumatology, 21 ((4)): (415-419). [PMID:21240619]
6. R Kawamori,N Inagaki,E Araki,H Watada,N Hayashi,Y Horie,A Sarashina,Y Gong,M von Eynatten,H J Woerle,K A Dugi. (2011-12-08) Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.. Diabetes, obesity & metabolism, 14 ((4)): (348-357). [PMID:22145698]
7. Michio Shimabukuro,Hiroaki Masuzaki,Masataka Sata. (2012-02-02) Intensive glucose lowering in cardiovascular risk management - unsolved questions - .. Circulation journal : official journal of the Japanese Circulation Society, 76 ((3)): (593-595). [PMID:22293455]
8. Devasier Bennet,Mohana Marimuthu,Sanghyo Kim,Jeongho An. (2012-08-14) Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery.. International journal of nanomedicine, 7 (3399-3419). [PMID:22888222]
9. Masahiro Inoue. (2012-09-22) Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.. Expert opinion on pharmacotherapy, 13 ((16)): (2257-2268). [PMID:22994875]
10. E Araki,R Kawamori,N Inagaki,H Watada,N Hayashi,Y Horie,A Sarashina,S Thiemann,M von Eynatten,K Dugi,H-J Woerle. (2012-11-21) Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.. Diabetes, obesity & metabolism, 15 ((4)): (364-371). [PMID:23163910]
11. Yuri Ono,Hiraku Kameda,Kyu Yong Cho. (2013-02-19) Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.. Expert opinion on pharmacotherapy, 14 ((4)): (361-370). [PMID:23414242]
12. Chiaki Seo,Masaya Sakamoto,Rimei Nishimura,Daisuke Tsujino,Kiyotaka Ando,Aya Morimoto,Kazunori Utsunomiya. (2013-05-03) Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.. Diabetes technology & therapeutics, 15 ((5)): (378-385). [PMID:23634671]
13. Bum-Ho Bin,Juyeon Seo,Seung Ha Yang,Eunkyung Lee,Hyunjung Choi,Kyu-Han Kim,Eun-Gyung Cho,Tae Ryong Lee. (2013-07-25) Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis.. Experimental dermatology, 22 ((8)): (541-546). [PMID:23879813]
14. Hyun Ju Do,Taeon Jin,Ji Hyung Chung,Ji Won Hwang,Min-Jeong Shin. (2014-01-07) Voglibose administration regulates body weight and energy intake in high fat-induced obese mice.. Biochemical and biophysical research communications, 443 ((3)): (1110-1117). [PMID:24388987]
15. Chikoto Hashiguchi,Shin-ichiro Kawamoto,Takayuki Kasai,Yasuhiro Nishi,Eiichi Nagaoka. (2014-05-23) Influence of an antidiabetic drug on biomechanical and histological parameters around implants in type 2 diabetic rats.. Implant dentistry, 23 ((3)): (264-269). [PMID:24844386]
16. Toshiyuki Takasu,Yuka Hayashizaki,Atsuo Tahara,Eiji Kurosaki,Shoji Takakura. (2014-10-15) Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter\xa02 inhibitor, in combination with oral antidiabetic drugs in mice.. Clinical and experimental pharmacology & physiology, 42 ((1)): (87-93). [PMID:25311502]
17. Hyang-Ki Choi,Minkyung Oh,Eun Ji Kim,Geun Seog Song,Jong-Lyul Ghim,Ji-Hong Shon,Ho-Sook Kim,Jae-Gook Shin. (2014-12-30) Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.. International journal of clinical pharmacology and therapeutics, 53 ((2)): (147-153). [PMID:25546164]
18. Hiroki Oe,Kazufumi Nakamura,Hajime Kihara,Kenei Shimada,Shota Fukuda,Tsutomu Takagi,Toru Miyoshi,Kumiko Hirata,Junichi Yoshikawa,Hiroshi Ito. (2015-06-19) Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.. Cardiovascular diabetology, 14 (83-83). [PMID:26084668]
19. Atsuo Tahara,Toshiyuki Takasu,Masanori Yokono,Masakazu Imamura,Eiji Kurosaki. (2015-10-10) Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.. Archives of pharmacal research, 39 ((2)): (259-270). [PMID:26450351]
20. Kenji Akahane,Kazuma Ojima,Ayaka Yokoyama,Toshihiro Inoue,Sumiyoshi Kiguchi,Satoshi Tatemichi,Hiroo Takeda,Yohsuke Imai. (2017-07-27) Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats.. Clinical and experimental pharmacology & physiology, 44 ((12)): (1263-1271). [PMID:28744906]
21. Xiaodan Liu,Jianan Feng,Yan Li. (2018-03-05) Preparation of carbon-functionalized magnetic graphene/mesoporous silica composites for selective extraction of miglitol and voglibose in rat plasma.. Talanta, 182 (405-413). [PMID:29501171]
22. Kemin Tan,Christine Tesar,Rosemarie Wilton,Robert P Jedrzejczak,Andrzej Joachimiak. (2018-05-16) Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase.. Protein science : a publication of the Protein Society, 27 ((8)): (1498-1508). [PMID:29761590]
23. R M Coleman,G Ojeda-Torres,W Bragg,D Fearey,P McKinney,L Castrodale,D Verbrugge,K Stryker,E DeHart,M Cooper,E Hamelin,J Thomas,R C Johnson. (2018-05-26) Saxitoxin Exposure Confirmed by Human Urine and Food Analysis.. Journal of analytical toxicology, 42 ((7)): (e61-e64). [PMID:29800291]
24. Atsuo Tahara,Yoshinori Kondo,Toshiyuki Takasu,Hiroshi Tomiyama. (2018-07-20) Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 105 (1033-1041). [PMID:30021338]
25. Zhi Xiang Ng,Nureen Farhana Rosman. (2019-03-25) In vitro digestion and domestic cooking improved the total antioxidant activity and carbohydrate-digestive enzymes inhibitory potential of selected edible mushrooms.. Journal of food science and technology, 56 ((2)): (865-877). [PMID:30906044]
26. Mai Sotoyama,Shinya Uchida,Chiaki Kamiya,Shimako Tanaka,Yasuharu Kashiwagura,Akio Hakamata,Keiichi Odagiri,Naoki Inui,Hiroshi Watanabe,Noriyuki Namiki. (2019-06-04) Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.. Chemical & pharmaceutical bulletin, 67 ((6)): (540-545). [PMID:31155559]
27. Shipra Bhansali,Anil Bhansali,Pinaki Dutta,Rama Walia,Veena Dhawan. (2020-01-25) Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study.. Journal of cellular and molecular medicine, 24 ((5)): (2832-2846). [PMID:31975558]
28. Junichi Kato,Yohei Shirakami,Taku Mizutani,Masaya Kubota,Hiroyasu Sakai,Takashi Ibuka,Masahito Shimizu. (2020-03-27) Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.. International journal of molecular sciences, 21 ((6)): [PMID:32210144]
29. Xiaolong Chen,Yuguo Zheng,Yinchu Shen. (2006-02-07) Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.. Current medicinal chemistry, 13 ((1)): (109-116). [PMID:16457643]
30. Makoto Hiki,Kazunori Shimada,Takashi Kiyanagi,Kosuke Fukao,Kuniaki Hirose,Hiromichi Ohsaka,Yoshifumi Fukushima,Atsumi Kume,Rie Matsumori,Katsuhiko Sumiyoshi,Tetsuro Miyazaki,Hirotoshi Ohmura,Takeshi Kurata,Takashi Miida,Hiroyuki Daida. (2010-06-04) Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.. Circulation journal : official journal of the Japanese Circulation Society, 74 ((7)): (1471-1478). [PMID:20519875]
31. Y Iwamoto,N Tajima,T Kadowaki,K Nonaka,T Taniguchi,M Nishii,J C Arjona Ferreira,J M Amatruda. (2010-07-02) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.. Diabetes, obesity & metabolism, 12 ((7)): (613-622). [PMID:20590736]
32. Xiu-mei Dai,Ning An,Jian-min Wu,Hui-yi Li,Qi-ming Zhang. (2011-02-26) Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products.. Yao xue xue bao = Acta pharmaceutica Sinica, 45 ((3)): (347-352). [PMID:21348424]
33. Keisuke Fujitaka,Hajime Otani,Fusakazu Jo,Hiromi Jo,Emiko Nomura,Masayoshi Iwasaki,Mitsushige Nishikawa,Toshiji Iwasaka. (2011-04-19) Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.. Endocrine journal, 58 ((6)): (425-432). [PMID:21498915]
34. Ryuzo Kawamori. (2011-07-20) [Evidence demonstrating the effect of voglibose for the prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese subjects with inpaired glucose tolerance].. Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 1 (663-670). [PMID:21766678]
35. T Narita,H Yokoyama,R Yamashita,T Sato,M Hosoba,T Morii,H Fujita,K Tsukiyama,Y Yamada. (2011-11-05) Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.. Diabetes, obesity & metabolism, 14 ((3)): (283-287). [PMID:22051162]
36. Yu Kataoka,Satoshi Yasuda,Yoshihiro Miyamoto,Kazuhiro Sase,Masami Kosuge,Kazuo Kimura,Yasunao Yoshimasa,Shunichi Miyazaki. (2012-01-14) Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.. Circulation journal : official journal of the Japanese Circulation Society, 76 ((3)): (712-720). [PMID:22240597]
37. Eberhard Standl,Oliver Schnell. (2012-04-18) Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.. Diabetes & vascular disease research, 9 ((3)): (163-169). [PMID:22508699]
38. Tomoko Kimura,Jinya Suzuki,Mai Ichikawa,Michiko Imagawa,Satsuki Sato,Miki Fujii,Yasuo Zenimaru,Satoru Inaba,Sadao Takahashi,Tadashi Konoshita,Isamu Miyamori. (2012-04-24) Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.. Diabetes technology & therapeutics, 14 ((7)): (545-551). [PMID:22519736]
39. . (2012-09-29) Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.. Prescrire international, 21 ((130)): (212-213). [PMID:23016254]
40. Makoto Ayaori,Naotsugu Iwakami,Harumi Uto-Kondo,Hiroki Sato,Makoto Sasaki,Tomohiro Komatsu,Maki Iizuka,Shunichi Takiguchi,Emi Yakushiji,Kazuhiro Nakaya,Makiko Yogo,Masatsune Ogura,Bonpei Takase,Takehiko Murakami,Katsunori Ikewaki. (2013-03-26) Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.. Journal of the American Heart Association, 2 ((1)): (e003277-e003277). [PMID:23525426]
41. Masayuki Yamaguchi,Takami Saji,Sachiko Mita,Kenneth Kulmatycki,Yan-Ling He,Kenichi Furihata,Kaneo Sekiguchi. (2013-06-21) Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.. International journal of clinical pharmacology and therapeutics, 51 ((8)): (641-651). [PMID:23782587]
42. Ho-Sook Kim,Minkyung Oh,Eun Ji Kim,Geun Seog Song,Jong-Lyul Ghim,Ji-Hong Shon,Dong-Hyun Kim,Jae-Gook Shin. (2014-08-28) Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.. International journal of clinical pharmacology and therapeutics, 52 ((11)): (1005-1011). [PMID:25161160]
43. Kaoru Noguchi,Minoru Hirota,Toru Miyoshi,Yoshinori Tani,Yoko Noda,Hiroshi Ito,Seiji Nanba. (2014-12-03) Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals.. Experimental and therapeutic medicine, 9 ((1)): (84-88). [PMID:25452780]
44. Clement Lo,Tadashi Toyama,Ying Wang,Jin Lin,Yoichiro Hirakawa,Min Jun,Alan Cass,Carmel M Hawley,Helen Pilmore,Sunil V Badve,Vlado Perkovic,Sophia Zoungas. (2018-09-25) Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.. The Cochrane database of systematic reviews, 9 (CD011798-CD011798). [PMID:30246878]
45. Ji-Won Kim,Ye-Jee Lee,Young-Hye You,Min Kyong Moon,Kun-Ho Yoon,Yu-Bae Ahn,Seung-Hyun Ko. (2018-11-27) Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes.. Journal of cellular biochemistry, [PMID:30474134]
46. Jin Bong Choi,Je Mo Yoo,Ye-Jee Lee,Jae Woong Kim,Seung-Ju Lee,Hee Youn Kim,Dong Sup Lee,Seung-Hyun Ko,Hyun-Sop Choe. (2020-04-07) Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes.. International neurourology journal, 24 ((1)): (21-28). [PMID:32252183]
47. Kentaro Ejiri,Toru Miyoshi,Hajime Kihara,Yoshiki Hata,Toshihiko Nagano,Atsushi Takaishi,Hironobu Toda,Seiji Nanba,Yoichi Nakamura,Satoshi Akagi,Satoru Sakuragi,Taro Minagawa,Yusuke Kawai,Nobuhiro Nishii,Soichiro Fuke,Masaki Yoshikawa,Kazufumi Nakamura,Hiroshi Ito. (2020-08-18) Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.. Journal of the American Heart Association, 9 ((16)): (e015103-e015103). [PMID:32805185]
48. Pooja Shah,Vishal Chavda,Snehal Patel,Shraddha Bhadada,Ghulam Md Ashraf. (2020-10-16) Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies.. Current gene therapy, 20 ((3)): (223-235). [PMID:33054705]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.